Aktieanalys

Saniona: Boehringer Ingelheim collaboration advances to lead optimization stage - Redeye

Redeye 14 Oct 10:16

Redeye has a positive view on the news from this morning, announcing that Saniona's collaboration with Boehringer Ingelheim has progressed to the lead optimization stage. This milestone has triggered a payment of approximately SEK5.7m to Saniona. The company remains eligible for up to EUR76.5m in additional milestones, as well as royalties, in the partnership focused on cognitive impairment in schizophrenia. We view this as an additional validation of Saniona's ion channel platform, with the milestone payment also contributing somewhat to the company's cash position.

Länk till analysen i sin helhet: https://www.redeye.se/research/1043268/saniona-boehringer-ingelheim-collaboration-advances-to-lead-optimization-stage?utm_source=finwire&utm_medium=RSS

Börskollens app – Högt betyg ⭐⭐⭐⭐⭐ och 250.000 nedladdningar

Ladda hem

Vårt nyhetsbrev – Utvalda börsnyheter och heta investeringscase varje vecka

Prenumerera

Nyheter om Saniona

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!